National Institute for Health and Clinical Excellence (NICE)
Specialist treatment necessary for patients with acute heart failure
All people admitted to hospital with suspected acute heart failure should receive treatment from a dedicated specialist heart failure team, according to NICE.
In latest guidance for acute heart failure, NICE has underlined the importance and benefits of specialist treatment for patients with the condition.
Acute heart failure is the leading cause of hospital admission in people over 65, and accounts for more than 67,000 people being admitted to hospital in England each year.
The condition is characterised by the heart failing to pump blood around the body at the right pressure, often as a result of damage to the heart muscle or heart valves but it can sometimes occur in people with no known previous heart dysfunction.
When a person has acute heart failure, they are usually admitted to an accident and emergency department, and those who are not very sick are then admitted to general medical wards or cardiology wards.
However, recent research has shown that while mortality rates for acute heart failure are improving, management and care of the condition still varies widely
An audit from the National Institute for Cardiovascular Outcomes Research found that half of patients admitted with heart failure in England and Wales ended up in non-specialist wards, and had a 54 per cent greater chance of dying as a result.
The audit also found that good clinical management by heart failure and cardiology specialists results in significantly better outcomes for patients.
To improve care and reduce variation in treatment, NICE has produced new guidance on the diagnosis and management of acute heart failure.
The guidance recommends that all hospitals admitting people with suspected heart failure should provide a specialist heart failure team that is based on a cardiology ward and provides outreach services.
In addition, they should ensure that all people being admitted to hospital with suspected heart failure have early and continuing input from a dedicated specialist heart failure team.
The guidance also covers the continuation of treatment with beta blockers after a person has had an episode of acute heart failure.
Dr Suzanna Hardman, Consultant Cardiologist and member of the guideline development group, said: “Untreated acute heart failure kills and can have a serious long-term impact on quality of life, but this can be transformed with specialist care.
“This guideline should ensure all patients admitted to hospital with acute heart failure are cared for by a specialist consultant-led multidisciplinary heart failure team.
“For most, this care will be delivered by a heart failure unit within a cardiology ward but for the few whose needs prioritise care elsewhere, the specialist team will be involved on an outreach basis.”
She added: “The use of tests (natriuretic peptides and early echocardiography) for possible new heart failure will prevent delayed diagnoses.
“The requirement for specialist team review within two weeks of going home will minimise readmissions and integrate acute and community care as outlined in NICE’s chronic heart failure guideline.
“This should result in a reduction in the number of people who die as a result of acute heart failure, improved well-being and less pressure on hospital beds."
Professor Jonathan Mant, Chair of the Guideline Development Group, commented: “The treatment patients with acute heart failure receive, and how successful that treatment is, varies depending on the unit they are admitted to.
“Patients admitted to hospital with heart failure should have early and continued input from a specialist heart failure team
Latest News from
National Institute for Health and Clinical Excellence (NICE)
NICE announces next steps for publication of its guideline on ME/CFS20/10/2021 14:20:00
NICE has today (20 October 2021) announced the next steps for publication of its updated guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS)
New draft guideline to help reduce health inequalities in people experiencing homelessness07/10/2021 09:15:00
NICE and the Centre for Homelessness Impact (CHI) have jointly published a new draft guideline to increase the access people experiencing homelessness have to health and social care services and improve their health outcomes.
NICE updates managing COVID guideline with new monoclonal antibody recommendations06/10/2021 11:15:00
NICE has updated its managing COVID-19 guideline to include new recommendations on using monoclonal antibodies to treat COVID-19 patients in hospital.
NICE recommends first treatment in two decades for sickle cell disease05/10/2021 11:15:00
Hundreds of people will be eligible for a new treatment for sickle cell disease following draft guidance published today (5 October).
People with advanced or metastatic urothelial cancer to get life-extending treatment01/10/2021 11:15:00
Around 130 people per year with untreated locally advanced or metastatic urothelial cancer will be eligible for a new life-extending treatment after NICE published final draft guidance yesterday (30 September 2021) recommending atezolizumab.
Update on the NICE ME/CFS guideline roundtable discussion22/09/2021 09:10:00
The roundtable meeting to discuss the updated guideline on the diagnosis and management of ME/CFS will be held on October 18th in London. It is being convened after publication of the guideline was paused when issues were raised by some professional groups during the pre-publication period
NICE and PHE recommend all employers give mental health training for managers17/09/2021 11:10:00
All managers should be given the skills to support employees with mental health issues, NICE and PHE have said in new guidance.
NICE recommends treatment for people with juvenile idiopathic arthritis10/09/2021 11:15:00
NICE yesterday (9 September 2021) published final draft guidance which recommends tofacitinib (also known as Xeljanz and made by Pfizer) as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis in people 2 years and older.